Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Awakn Life Sciences Corp. (AWKNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.6200-0.0045 (-0.28%)
At close: 10:52AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.6245
Open1.6200
BidN/A x N/A
AskN/A x N/A
Day's Range1.6200 - 1.6200
52 Week Range1.3947 - 1.9100
Volume30,000
Avg. Volume2,194
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th

    Virtual Investor Conferences in partnership with KCSA Strategic Communications today announced the agenda for the upcoming KCSA Psychedelics Virtual Investor Conference. Individual investors, institutional investors, advisors, and analysts are invited to attend the two-day program beginning Wednesday, October 13, 2021, at 9:45 a.m. ET.

  • Newsfile

    Awakn Life Sciences to Present at the KCSA Psychedelics Virtual Investor Conference on October 13th

    Toronto, Ontario--(Newsfile Corp. - October 8, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat Addiction, announced today that Anthony Tennyson, CEO of Awakn Life Sciences, will participate in the KCSA Psychedelics Investor Conference to be held at VirtualInvestorConferences.com on October 13-14, 2021. Anthony Tennyson will present live on Wednesday, Oc

  • Newsfile

    Awakn Life Sciences Announces Closing of Acquisition of Leading Ketamine-Assisted Psychotherapy Clinic in Norway

    Transaction concludes with the launch of "Awakn Clinics Oslo AS" as part of Awakn Life Sciences Nordic Expansion Toronto, Ontario--(Newsfile Corp. - October 5, 2021) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a biotechnology company developing and delivering psychedelic therapeutics (medicines and therapies) to treat addiction, is pleased to announce the closing of its acquisition of Axonklinikken AS ("Axon"), a leading ketamine-assisted psychot

Advertisement
Advertisement